Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
202 50 0 TRIL
Emcee:  tuck Type:  Unmoderated
The following is how Trillium now thinks of itself as of 8/31/2017:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

The board logo is CD47 in complex with SIRP, the pathway targeted by the lead program.

Website: Trillium Therapeutics
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
202FTSV - about the same MC as SURF.semi_infinite -last Thursday
201 latest FTSV S-1.... >> In addition, unless we specifically state otherwiscaram(o)uche-last Wednesday
200Bispecific, CD47 x CD20: Zuanic-last Wednesday
199Well, my comment was, of course, silly. Lotsa shares, any category, that donscaram(o)uche-June 11
198 Here’s another link to AWM’s filings re TRIL: Confusing, but doesn’tBulbaMan-June 11
197Corresponding increase in preferred shares, if all of that data is correct. Wouscaram(o)uche-June 11
196Bulba, How does 11,000,000 drop to 954,000? Something doesn't seem right hBladerunner17-June 11
195Thanks! (eom)scaram(o)uche-June 11
194 Also found AWM Trillium info here: (Sort alphabetically on Security cBulbaMan-June 11
193>> Hope the Forty Seven IPO catches.... << Needs a reverse split, scaram(o)uche-June 11
192The RSI is strong in the bullish zone and the MACD is trying to cross back up. OAlejandroo Green-June 11
191Just parking a link. Don't know if this is THE preferred, if it's just scaram(o)uche-June 11
190Yeah Rick, I was surprised SURF didn’t get an IPO surge, actually closing down oBulbaMan-June 9
189Market cap $400m..... One product in clinical testing, phase I. (I knscaram(o)uche-June 9
188 >>> “...for allowing that last round of hiring to be sourced from a VaBulbaMan-June 8
187So Nic finally had the nuts to hire the best person available? Kudos!! Needed dscaram(o)uche-June 7
186 Just absolutely disgusting. jay arnold? @jayabacus10h10 hours ago More Oscaram(o)uche-June 6
185Fourty Seven files for IPO. It will have 177M shares outstanding after offeringsemi_infinite -June 1
184Once again, shareholders are paying for the PD1 or PDL1 inhibitor. Or perhaps Dscaram(o)uche-May 29
183Thnx, indeed very good results for small # subjects enrolled. CRs after Rituxan Miljenko Zuanic-May 17
182Could this be the institutional recreation to 47 data? d18rn0p25nwr6d.cloudfronsemi_infinite -May 17
181Competitor 47 out with good ASCO data: Forty Seven P1/2 data Cheers, Tucktuck-May 17
180I took bite size chunks when it dropped below $6 recently. It seems the probabisemi_infinite -May 15
179I have bought a little more over the last few weeks. Breaking the T-cell group iBiomaven-May 15
178Peter et. al., Are any of you buying more here? BladerunnerBladerunner17-May 15
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.